Grant: Alliance Grants
Simon Fraser University
$75,000.00
Development of sensor technology for ultrasensitive detection of HPV DNA
FY 2024-25
Summary
Human papillomavirus (HPV) is one of the most powerful human carcinogens, having a causal role in all cervical cancer (~530,000 cases per year) and 88% of anal cancer (~24,000 cases per year). HPV can also cause cancer of the vulva, vagina, penis, and throat. Routine screening for women 21 - 65 years of age as well as HPV vaccinations can help prevent cancers. In the UK, USA, and other developed countries at least 20-30% of screening aged women have never been screened or were not screened within the last 5 years. Urine testing of HPV DNA is a promising screening method because of its non-invasive nature and favourable acceptability by women.
This research focuses on the development of a new diagnostic platform for the rapid and ultra-sensitive detection of HPV DNA from urine testing. The project is led by a multidisciplinary team consisting of Dr. Peter Unrau, Molecular Biology and Biochemistry and Dr. Michael Adachi, School of Engineering Science, in partnership with two Canadian industry partners Gene Bio Medical and Geno10x Biosciences. Dr. Unrau's team has developed a quantum-dot enabled fluorescence based test for the detection of nucleic acids at femtomolar (fM) concentrations. Dr. Adachi's team has developed a new electronic diode sensor using aptamer functionalization to detect a small protein called TNF-alpha also at fM concentrations. Based on these technologies, Dr. Unrau and Dr. Adachi's team will collaborate to develop a new method for the detection of HPV DNA. The industry partners will guide the research teams in developing new technologies compatible with manufacturing processes.
Program
Alliance Grants
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
598488-2024
Name nom
Adachi, Michael MM
Department département
Engineering Science, School of
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
75000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Development of sensor technology for ultrasensitive detection of HPV DNA
Keywords
biomedical; detection; diagnostics; electronics; fabrication; hpv dna; human papillomavirus (hpv); point-of-care; sensors; urine
Application summary
Human papillomavirus (HPV) is one of the most powerful human carcinogens, having a causal role in all cervical cancer (~530,000 cases per year) and 88% of anal cancer (~24,000 cases per year). HPV can also cause cancer of the vulva, vagina, penis, and throat. Routine screening for women 21 - 65 years of age as well as HPV vaccinations can help prevent cancers. In the UK, USA, and other developed countries at least 20-30% of screening aged women have never been screened or were not screened within the last 5 years. Urine testing of HPV DNA is a promising screening method because of its non-invasive nature and favourable acceptability by women.
This research focuses on the development of a new diagnostic platform for the rapid and ultra-sensitive detection of HPV DNA from urine testing. The project is led by a multidisciplinary team consisting of Dr. Peter Unrau, Molecular Biology and Biochemistry and Dr. Michael Adachi, School of Engineering Science, in partnership with two Canadian industry partners Gene Bio Medical and Geno10x Biosciences. Dr. Unrau's team has developed a quantum-dot enabled fluorescence based test for the detection of nucleic acids at femtomolar (fM) concentrations. Dr. Adachi's team has developed a new electronic diode sensor using aptamer functionalization to detect a small protein called TNF-alpha also at fM concentrations. Based on these technologies, Dr. Unrau and Dr. Adachi's team will collaborate to develop a new method for the detection of HPV DNA. The industry partners will guide the research teams in developing new technologies compatible with manufacturing processes.